| Quarterly Financials | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
Revenue  | 64 | 64 | 75 | 79 | 71 | 72 | 99 | 95 | 69 | 68 | 74 | 72 | 71 | 88 | 76 | 75 | 65 | 78 | 87 | 107 | 95 | 101 | 103 | 106 | 69 | 87 | 97 | 119 | 83 | 94 | 98 | 110 | 73 |
| Expenses | 57 | 55 | 64 | 62 | 62 | 61 | 85 | 84 | 64 | 63 | 65 | 62 | 60 | 81 | 67 | 65 | 59 | 67 | 76 | 90 | 82 | 87 | 88 | 90 | 63 | 77 | 85 | 102 | 74 | 83 | 85 | 94 | 68 |
| EBITDA | 7 | 9 | 11 | 17 | 9 | 11 | 13 | 11 | 4 | 5 | 9 | 9 | 11 | 8 | 8 | 10 | 7 | 11 | 11 | 16 | 13 | 14 | 16 | 16 | 6 | 11 | 13 | 17 | 9 | 11 | 13 | 16 | 6 |
| Operating Profit % | 11 % | 13 % | 15 % | 13 % | 12 % | 14 % | 13 % | 11 % | 5 % | 7 % | 11 % | 10 % | 15 % | 9 % | 10 % | 12 % | 8 % | 13 % | 12 % | 14 % | 12 % | 12 % | 13 % | 15 % | 7 % | 11 % | 12 % | 13 % | 10 % | 10 % | 12 % | 13 % | 6 % |
| Depreciation | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 |
| Interest | 2 | 3 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 3 | 3 | 2 | 1 | 1 | 1 | 2 | 1 | 2 | 1 | 2 | 2 | 3 | 3 | 3 | 3 | 3 |
| Profit Before Tax | 3 | 4 | 7 | 11 | 4 | 5 | 8 | 5 | -2 | -2 | 2 | 3 | 4 | 1 | 2 | 3 | 0 | 4 | 6 | 11 | 8 | 8 | 10 | 10 | 0 | 5 | 7 | 11 | 1 | 3 | 6 | 8 | -2 |
| Tax | 1 | 1 | 1 | 3 | 0 | 1 | 2 | 3 | -3 | -1 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 2 | 4 | 2 | 3 | 3 | 3 | 0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 | -1 |
| Net Profit | 2 | 3 | 6 | 8 | 4 | 3 | 6 | 2 | 0 | -1 | 2 | 2 | 3 | 1 | 1 | 2 | 0 | 3 | 4 | 7 | 5 | 5 | 7 | 7 | 0 | 4 | 5 | 8 | 1 | 2 | 4 | 5 | -2 |
| EPS in ₹ | 2.66 | 1.79 | 7.81 | 4.84 | 2.35 | 2.08 | 3.65 | 1.43 | 0.05 | -0.37 | 0.94 | 1.41 | 2.02 | 0.73 | 0.80 | 0.95 | 0.12 | 2.00 | 2.51 | 4.33 | 3.17 | 3.35 | 1.35 | 1.48 | 0.05 | 0.85 | 0.98 | 1.66 | 0.18 | 0.49 | 0.82 | 1.01 | -0.38 |
Zim Laboratories
Zim Laboratories
68.93
-0.31
(-0.45%)
Key Fundamentals
Market Cap
337.40 Cr
EPS
2.50
PE Ratio
35.73
Dividend Yield
0.00 %
Industry
Healthcare 52 Week High
128.00
52 Week Low
67.00
PB Ratio
1.34
Debt to Equity
0.47
Sector
Pharmaceuticals Actual
Company News
View All News
ZIM Laboratories Seeks Shareholder Approval for Re-appointment of Two Whole-time Directors via Postal Ballot
Oct 13, 2025
Oct 13, 2025ZIM Laboratories Limited has issued a postal ballot notice seeking shareholder approval for the re-appointment of Mr. Niraj Dhadiwal and Mr. Prakash Sapkal as Whole-time Directors for a two-year term from October 1, 2025, to September 30, 2027. The e-voting period runs from October 15 to November 13, 2025. Both directors will receive remuneration packages including fixed salary up to Rs. 1.50 crores and performance-linked incentives up to Rs. 50 lakhs, along with perquisites such as medical insurance, car with driver, and telephone facilities. The company has appointed Ms. Roshni Jethani as scrutinizer for the postal ballot process, with results to be announced by November 15, 2025. Both directors have over 30 years of experience in the pharmaceutical sector, with Dhadiwal focusing on business development and Sapkal on operations.
ZIM Laboratories Limited's Board of Directors approved the re-appointment of Mr. Niraj Dhadiwal and Mr. Prakash Sapkal as Whole-Time Directors for a two-year term starting October 1, 2025. The decision was made during a board meeting held on September 19, 2025, following recommendations from the Nomination and Remuneration Committee. Both appointments are subject to shareholder approval. Mr. Dhadiwal, a pharmacy graduate with business management diploma, has been with the company for nearly three decades and serves as Director – Business Development, overseeing business development and marketing functions. Mr. Sapkal, a pharmacy graduate with MBA, has been associated with the company for 26 years and has handled key operations in various capacities including Production Manager and Vice President – Operations. Both directors are confirmed to not be debarred from holding directorial positions and are not related to any other directors on the board.
ZIM Laboratories Approves Closure of UAE Subsidiary, Reports 12.3% Revenue Decline in Q1 FY26Aug 07, 2025
ZIM Laboratories Limited's Board approved the closure of its step-down subsidiary ZIM Laboratories Middle East DMCC, subject to UAE regulatory approvals. The subsidiary contributed nil revenue and net worth during the last financial year. The company reported Q1 FY26 total operating income of ₹718 million, down 12.3% from ₹818 million in Q1 FY25, primarily due to supply difficulties with legacy clients caused by geo-political issues in Middle East and Bangladesh markets. EBITDA declined 36.7% to ₹57 million with margins falling to 7.9% from 11%. The company posted a net loss of ₹19 million compared to ₹9 million profit in Q1 FY25. Export revenue decreased 15.2% to ₹602 million while India business grew 30.2% to ₹100 million. ZIM received 2 marketing authorizations in Australia and invested ₹79 million in R&D, representing 11% of total operating income. The company earned ₹45 million in dossier licensing milestone payments during the quarter.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,687.00 | #1 4,04,767.81 | 39.10 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 60.73 | |
6,438.50 | 1,72,289.10 | 74.71 | 9,712.00 | 18.67 | 2,191 | 26.74 | 57.08 | |
1,568.10 | 1,27,948.20 | 23.76 | 28,409.50 | 7.12 | 5,291 | 9.88 | 50.34 | |
3,576.50 | 1,21,718.50 | 60.78 | 11,539.40 | 6.99 | 1,911 | 19.91 | 50.97 | |
1,289.40 | 1,07,189.40 | #1 18.69 | 33,741.20 | 16.73 | 5,725 | -0.38 | 57.78 | |
1,001.25 | 1,02,017.00 | 21.65 | 23,511.00 | 18.55 | 4,615 | 2.60 | 50.49 | |
2,406.50 | 99,751.30 | 52.11 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 35.88 | |
1,918.70 | 87,829.30 | 23.59 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 42.45 | |
5,432.00 | 65,467.80 | 28.04 | 13,458.30 | 3.70 | 2,216 | 21.39 | 44.72 | |
1,099.40 | 63,580.40 | 18.93 | 32,345.60 | 9.43 | 3,484 | -10.24 | 50.73 |
Growth Rate
Revenue Growth
3.27 %
Net Income Growth
-29.07 %
Cash Flow Change
152.76 %
ROE
-33.24 %
ROCE
-9.59 %
EBITDA Margin (Avg.)
3.13 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 265 | 256 | 259 | 298 | 329 | 325 | 325 | 342 | 342 | 447 | 472 |
| Fixed Assets | 87 | 92 | 89 | 94 | 106 | 116 | 107 | 106 | 109 | 161 | 164 |
| Current Assets | 168 | 154 | 154 | 173 | 194 | 182 | 192 | 212 | 191 | 228 | 231 |
| Capital Work in Progress | 6 | 3 | 4 | 8 | 13 | 10 | 11 | 12 | 27 | 42 | 71 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 172 | 161 | 166 | 196 | 209 | 200 | 208 | 224 | 206 | 244 | 237 |
| Total Liabilities | 265 | 256 | 259 | 298 | 329 | 325 | 325 | 342 | 342 | 447 | 472 |
| Current Liabilities | 133 | 122 | 113 | 141 | 155 | 143 | 142 | 146 | 111 | 159 | 166 |
| Non Current Liabilities | 38 | 35 | 28 | 20 | 22 | 28 | 22 | 20 | 30 | 49 | 53 |
| Total Equity | 94 | 99 | 118 | 137 | 151 | 154 | 161 | 176 | 200 | 239 | 252 |
| Reserve & Surplus | 86 | 91 | 110 | 129 | 135 | 138 | 145 | 160 | 152 | 190 | 202 |
| Share Capital | 8 | 8 | 8 | 8 | 16 | 16 | 16 | 16 | 49 | 49 | 49 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -7 | -0 | -0 | 1 | -1 | 1 | -0 | 2 | 3 | 3 | -8 |
| Investing Activities | -9 | -12 | -7 | -26 | -21 | -19 | -6 | -14 | -36 | -73 | -40 |
| Operating Activities | 6 | 22 | 32 | 37 | 35 | 22 | 32 | 49 | 38 | 16 | 41 |
| Financing Activities | -4 | -10 | -25 | -10 | -15 | -2 | -26 | -33 | 1 | 60 | -9 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 33.26 % | 33.26 % | 33.26 % | 33.26 % | 33.26 % | 33.26 % | 33.26 % | 33.26 % | 33.26 % | 33.26 % | 33.26 % | 33.26 % | 33.26 % | 33.26 % | 33.26 % | 33.26 % | 33.26 % | 33.26 % | 33.26 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.00 % | 0.00 % | 0.21 % | 0.01 % | 0.03 % | 0.00 % |
| DIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.11 % | 0.10 % | 0.24 % | 0.24 % | 0.24 % | 0.24 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 30.73 % | 51.92 % | 51.96 % | 50.67 % | 50.77 % | 51.15 % | 50.96 % | 51.57 % | 51.57 % | 49.90 % | 50.74 % | 50.92 % | 49.01 % | 49.21 % | 45.48 % | 44.39 % | 47.78 % | 47.50 % | 48.20 % |
| Others | 36.01 % | 14.81 % | 14.77 % | 16.06 % | 15.97 % | 15.59 % | 15.78 % | 15.17 % | 15.16 % | 16.84 % | 15.99 % | 15.82 % | 17.72 % | 17.42 % | 21.15 % | 21.90 % | 18.71 % | 18.96 % | 18.30 % |
| No of Share Holders | 4,600 | 4,887 | 4,610 | 3,646 | 3,561 | 3,569 | 3,643 | 5,595 | 5,879 | 8,982 | 15,305 | 17,342 | 17,100 | 17,483 | 17,716 | 17,450 | 17,448 | 16,641 | 17,282 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
 Bonus | 1:1 | 04 Oct 2018 | 55.33 | 0.00 | |
| 29 Jun 2022 |  Extraordinary General Meeting | NA | 29 Jun 2022 | 77.67 | 63.50 |
| 22 Dec 2022 | Bonus | 2:1 | 22 Dec 2022 | 105.18 | 110.83 |
| 27 Jun 2024 |  Annual General Meeting | NA | 27 Jun 2024 | 102.30 | 105.00 |
| 09 Nov 2024 |  Quarterly Result Announcement | NA | 09 Nov 2024 | 106.99 | 113.35 |
| 10 Feb 2025 | Quarterly Result Announcement | NA | 10 Feb 2025 | 101.05 | 106.72 |
| 20 May 2025 | Quarterly Result Announcement | NA | 20 May 2025 | 88.41 | 92.99 |
| 27 Jun 2025 | Annual General Meeting | NA | 27 Jun 2025 | 88.14 | 112.62 |
| 07 Aug 2025 | Quarterly Result Announcement | NA | 07 Aug 2025 | 111.70 | 79.30 |
Announcements
Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 14, 2025
Oct 14, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotOct 13, 2025
Oct 13, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 08, 2025
Oct 08, 2025Closure of Trading WindowSep 26, 2025
Sep 26, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSSep 19, 2025
Sep 19, 2025Announcement under Regulation 30 (LODR)-Change in ManagementSep 19, 2025
Sep 19, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 14, 2025
Aug 14, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 12, 2025
Aug 12, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 08, 2025
Aug 08, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Change in ManagementAug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Investor PresentationAug 07, 2025
Aug 07, 2025Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations 2015Aug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-AcquisitionAug 07, 2025
Aug 07, 2025Results- Financial Results For Quarter Ended 30Th June 2025Aug 07, 2025
Aug 07, 2025Board Meeting Outcome for Outcome Of Board Meeting Held On 07Th August 2025Aug 07, 2025
Aug 07, 2025Reply To Clarification Sought On Price MovementAug 07, 2025
Aug 07, 2025Clarification Sought On Movement Of Price Of The CompanyAug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 06, 2025
Aug 06, 2025Clarification sought from Zim Laboratories LtdAug 06, 2025
Aug 06, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 04, 2025
Aug 04, 2025Announcement Under Regulation 30 Of The SEBI (LODR) Regulations 2015Aug 01, 2025
Aug 01, 2025Board Meeting Intimation for Consideration And Approval Of The Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter Ended 30Th June 2025.Jul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 28, 2025
Jul 28, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 22, 2025
Jul 22, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 21, 2025
Jul 21, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionJul 11, 2025
Jul 11, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 10, 2025
Jul 10, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportJun 27, 2025
Jun 27, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMJun 27, 2025
Jun 27, 2025Closure of Trading WindowJun 26, 2025
Jun 26, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionJun 19, 2025
Jun 19, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 17, 2025
Jun 17, 2025Reg. 34 (1) Annual Report.Jun 05, 2025
Jun 05, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 04, 2025
Jun 04, 2025Announcement Under Regulation 30 - Letters Sent To ShareholdersJun 03, 2025
Jun 03, 2025Notice Of The 41St Annual General Meeting Of The CompanyJun 03, 2025
Jun 03, 2025Reg. 34 (1) Annual Report.Jun 03, 2025
Jun 03, 2025Intimation Of Annual General Meeting To Be Held On Intimation Of Date Of Annual General MeetingJun 03, 2025
Jun 03, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 29, 2025
May 29, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 26, 2025
May 26, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 23, 2025
May 23, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 22, 2025
May 22, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 22, 2025
May 22, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 21, 2025
May 21, 2025Q4 & FY25 - Earnings PresentationMay 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMay 20, 2025
May 20, 2025Results - Financials For The Quarter And Year Ended 31St March 2025May 20, 2025
May 20, 2025Board Meeting Outcome for Outcome Of Board Meeting Held On 20.05.2025May 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 14, 2025
May 14, 2025Technical Indicators
RSI(14)
Neutral 39.22
ATR(14)
Less Volatile 2.68
STOCH(9,6)
Neutral 23.22
STOCH RSI(14)
Neutral 69.33
MACD(12,26)
Bullish 0.16
ADX(14)
Strong Trend 26.52
UO(9)
Bearish 37.34
ROC(12)
Downtrend And Accelerating -1.38
WillR(14)
Neutral -72.07
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
